



# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20221
WWW.HEPIG. GOV

UNITED STATES TAR		Washington, D.C. 20231	
	T ATTO	RNEY DOCKET NO. C	CONFIRMATION NO.
FIRST NAMED INVENTOR	ATTO	TAN-285	5674
PRI ICATION NO. FILING DATE Hideki Umeyama		1711	
09/834,886		- OMF	· D
0,102.11		EXAMINE	

05/22/2002

SHERMAN & SHALLOWAY 413 North Washington Street Alexandria, VA 22314

EXAMINER FERNSTROM, KURT

PAPER NUMBER ART UNIT

3712

DATE MAILED: 05/22/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

		.s.y			
	Application No.	Applicant(s)			
Office Action Summary	09/834,886	UMEYAMA ET AL.			
Office Action Summary	Examiner	Art Unit			
The MAILING DATE of this communication com	Kurt Fernstrom	3712			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Peri d for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
1) Responsive to communication(s) filed on	·	•			
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>					
4)⊠ Claim(s) <u>1-3 and 5-8</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-3 and 5-8</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.  Application Papers					
9)⊠ The specification is objected to by the Examiner.					
10)⊠ The drawing(s) filed on is/are: a)□ accepted or b)⊠ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) ☐ The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a)⊠ All b)□ Some * c)□ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal P	(PTO-413) Paper No(s) atent Application (PTO-152)			

Serial Number: 09/834,886 Page 2

Art Unit: 3712

#### **DETAILED ACTION**

## Specification

1. The disclosure is objected to because of the following informalities: The specification appears to be a literal translation into English from a foreign document and is replete with grammatical and idiomatic errors..

Appropriate correction is required.

# **Drawings**

2. The drawings are objected to as failing to comply with 37 CFR 1.84(p)(5) because they do not include the following reference sign(s) mentioned in the description: 6, 7, 8, 9 and 10. A proposed drawing correction or corrected drawings are required in reply to the Office action to avoid abandonment of the application. The objection to the drawings will not be held in abeyance.

#### Claim Objections

3. Claim 3 is objected to because of the following informalities: The claim contains grammatical and idiomatic errors. Appropriate correction is required.

with grammatical and idiomatic errors.

•

Serial Number: 09/834,886 Page 3

Art Unit: 3712

## Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- 5. Claim 1 is rejected under 35 U.S.C. 102(a) as being anticipated by Sugiura, et al, "Creating Cataract in a Pig Eye" ("Sugiura"). Sugiura discloses a model of an eye with cataract comprising a pig's eye which has hardening chemicals injected into the lens.

## Claim Rejections - 35 USC § 103

- 6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 7. Claims 2, 3 and 5 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sugiura. While Sugiura does not disclose that the lens capsule is empty as claimed in claims 2 and 3, injecting chemicals into an empty lens capsule would have been obvious to one of ordinary skill in the art as an aesthetic choice of design and for the purpose of allowing the user to simulate a cataract solely using chemicals. Also, although the location of the injection of claim 5 is not

.4

Serial Number: 09/834,886

Art Unit: 3712

disclosed by Sugiura, the claimed location does not appear to yield any unexpected advantages over the location disclosed by Sugiura, and thus would also have been obvious to one of ordinary skill in the art as an aesthetic choice of design.

8. Claims 6-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Creating Cataract in view of Wilder, NCSU Chemical Engineering ("Wilder"). Crating Cataract discloses all of the limitations of claims 5-7 with the exception of the use of dibenzylidene sorbitol.

Dibenzylidene sorbitol is a known gelling agent which forms three dimensional fibrillar networks in organic substances, as disclosed by Wilder. It would have been obvious to one of ordinary skill in the relevant art to modify the model disclosed by Creating Cataract by providing dibenzylidene sorbitol for the purpose of hardening the eye to produce a simulated cataract.

#### Conclusion

- 9. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Brenner discloses a model of an eye with cataract comprising a pig's eye with hardening chemicals injected into it.
- .10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kurt Fernstrom whose telephone number is (703) 305-0303.

KF

May 16, 2002

Kien T. Nguy Primary Examiner

Page 4